PF-07985819 / Pfizer - LARVOL DELTA

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Infectious Disease • Influenza • Respiratory Diseases